Kansas Sues Pfizer, Says Company ‘Misled’ Public on COVID-19 Vaccine

Lawsuit is seeking damages and a declaration that Pfizer violated agreements with the state.

Kansas on June 17 sued Pfizer, alleging the pharmaceutical giant “misled” members of the public with various claims about its COVID-19 vaccine.

Pfizer, for instance, said on April 1, 2021, that there were “no serious safety concerns through up to six months following second dose” of the vaccine it makes with Germany’s BioNTech, the lawsuit notes.

But documents made public through a lawsuit showed that Pfizer’s adverse events database, which includes reported issues following vaccination from around the world, already contained 158,893 adverse events as of Feb. 28, 2021.

“Pfizer’s representations that its COVID-19 vaccine did not have any safety concerns was inconsistent with the adverse events data it possessed,” the suit, filed by Kansas Attorney General Kris Kobach states. “Pfizer concealed, suppressed, or omitted material facts it possessed showing significant safety concerns associated with Pfizer’s COVID-19 vaccine.”

The suit also highlights how Pfizer in the same press release said that vaccinated trial participants enjoyed 91.3 percent protection against COVID-19 up to six months after a second dose.

Documents released later, though, showed that Pfizer recorded 83.7 percent effectiveness among trial participants at four months after a second dose, while finding indications in blood samples that effectiveness was waning even more at six months.

Pfizer disclosed the waning effectiveness on July 28, 2021, in a preprint paper.

Its press release that day mentioned positive findings from a different study but omitted mention of the preprint paper or how it had found signs of waning protection.

“Pfizer’s concealment, suppression, and omission of the waning effectiveness of its COVID-19 vaccine allowed Pfizer to profit from vaccinations of Kansans who may have been deterred from Pfizer’s COVID-19 vaccine had they known about its waning effectiveness,” the suit states.

In the second quarter of 2021, Pfizer made nearly $8 billion from its COVID-19 vaccine.

The suit also notes that Albert Bourla, Pfizer’s CEO, said in early 2023 that “We constantly review and analyze the data“ and ”we’ve seen not a single signal although we have distributed billions of doses.”

By Zachary Stieber

Read Full Article on TheEpochTimes.com

State of Kansas, ex rel. Kris Kobach v Pfizer